Medgenics Inc Appoints Bill Gantz to its Board of Directors (7450Q)
17 10월 2013 - 9:00PM
UK Regulatory
TIDMMEDG TIDMMEDU
RNS Number : 7450Q
Medgenics Inc
17 October 2013
Press Release 17 October 2013
Medgenics Appoints Biopharmaceutical Industry Veteran Bill Gantz
to its Board of Directors
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) ("the
Company"), the developer of a novel technology for the sustained
production and delivery of therapeutic proteins in patients using
their own tissue, announces the appointment of Wilbur H. (Bill)
Gantz to the Company's Board of Directors effective October 16,
2013. With this appointment, the size of the Medgenics board
increases to 10 directors.
Mr. Gantz is President of PathoCapital, an investor in
healthcare companies. He previously served as Executive Chairman
and Chief Executive Officer of Ovation Pharmaceuticals, Inc., which
was sold to Lundbeck, AG in 2009, and as Chairman, Chief Executive
Officer and President of PathoGenesis Corporation, a
biopharmaceutical company that was sold to Chiron, Inc. in 2000.
Prior to founding PathoGenesis, from 1987 to 1992 he served as
President of Baxter International, Inc., a manufacturer and
marketer of healthcare products. He joined Baxter in 1966 and held
various management positions, including Vice President, Europe and
President, International Division, prior to being named Executive
Vice President and Chief Operating Officer in 1980.
"Bill is a prominent and highly regarded figure in the
biopharmaceutical industry, and we are delighted to welcome him to
our Board of Directors. He has demonstrated leadership at both
global pharmaceutical companies as well as at a series of
entrepreneurial biotechnology companies that he built and guided to
success," said Mike Cola, President and Chief Executive Officer of
Medgenics. "Bill's insights will be instrumental in guiding
Medgenics as we advance our clinical development programs and build
a successful biotechnology company."
"I am delighted to be joining Medgenics at this important
juncture in its clinical development," said Mr. Gantz. "The
Company's novel, technology platform holds great potential to
change the paradigm for therapeutic proteins across a number of
chronic conditions. I look forward to working with the Medgenics
team and my fellow directors to advance the development of this
promising platform technology."
Mr. Gantz is currently Executive Chairman, Naurex, Inc., a
biotechnology company developing central nervous system
therapeutics. He is a Vice Chairman of the Board of Trustees and
Chair of the Committee on Science of the Field Museum of Natural
History in Chicago. He is the former Chairman of the Board of
Harris Financial Corporation and a former director of the Gillette
Company, W.W. Grainger, Inc., Gambio, Inc. and Baxter
International. He is a past trustee of Princeton University. Mr
Gantz is 75 years old. In addition to the above, is a partner of
Adam Street Partners, LLP and a director of Neurowave, Inc.
Mr. Gantz holds a BA degree from Princeton University, where he
graduated cum laude, and an MBA from Harvard Business School.
In connection with Mr. Gantz's appointment, the Compensation
Committee of Medgenics' Board of Directors granted Mr. Gantz an
inducement award under the Company's Stock Incentive Plan
consisting of stock options covering up to 300,000 shares of the
Company's common stock, $0.0001 par value per share ("Common
Stock"), at a per share exercise price of $6.29, representing the
closing price of the Company's Common Stock on the date of the
grant. These options have a five-year term, with 100,000 shares of
Common Stock underlying such options vesting immediately and the
remaining underlying shares vesting equally on October 16, 2014 and
October 16, 2015, subject to his continuous service through each
vesting date.
About Medgenics
Medgenics is developing and commercializing Biopump(TM), a
proprietary tissue-based platform technology for the sustained
production and delivery of therapeutic proteins using the patient's
own tissue for the treatment of a range of chronic diseases
including anemia, hepatitis, among others. For more information,
please visit www.medgenics.com.
Forward-looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and as that term is defined
in the Private Securities Litigation Reform Act of 1995, which
include all statements other than statements of historical fact,
including (without limitation) those regarding the company's
financial position, its development and business strategy, its
product candidates and the plans and objectives of management for
future operations. The company intends that such forward-looking
statements be subject to the safe harbors created by such laws.
Forward-looking statements are sometimes identified by their use of
the terms and phrases such as "estimate," "project," "intend, "
"forecast," "anticipate," "plan," "planning, "expect," "believe,"
"will," "will likely," "should," "could," "would," "may" or the
negative of such terms and other comparable terminology. All such
forward-looking statements are based on current expectations and
are subject to risks and uncertainties. Should any of these risks
or uncertainties materialize, or should any of the company's
assumptions prove incorrect, actual results may differ materially
from those included within these forward-looking statements.
Accordingly, no undue reliance should be placed on these
forward-looking statements, which speak only as of the date made.
The company expressly disclaims any obligation or undertaking to
disseminate any updates or revisions to any forward-looking
statements contained herein to reflect any change in the company's
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based.
As a result of these factors, the events described in the
forward-looking statements contained in this release may not
occur.
Contacts:
LHA
Anne Marie Fields,
afields@lhai.com
@LHA_IR_PR 212-838-3777
Abchurch Communications
Joanne Shears / Jamie Hooper
/ Harriet Rae
harriet.rae@abchurch-group.com +44 207 398 7718
Oriel Securities (NOMAD & Joint
Broker)
Jonathan Senior / Giles Balleny +44 207 710 7617
SVS Securities plc (Joint Broker)
Alex Brearley +44 203 700 0100
-Ends-
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAGGGQUUUPWUBM
Medgenics(Regs) (LSE:MEDG)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Medgenics(Regs) (LSE:MEDG)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024